Sepracor (SEPR) CEO Buys 50K Shares
More News related to SEPR
- Susquehanna Upgrades Sepracor (SEPR) to Neutral
- J.P. Morgan Initiates Coverage on Sepracor (SEPR) with a Neutral
- Sepracor (SEPR) Reports Positive Results from 3 Phase III Trials of Eslicarbazepine Acetate
- New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
- ALVESCO(R) (Ciclesonide) Inhalation Aerosol Now Available in U.S. for Treatment of Asthma
More News related to Insider Trades
- Chesapeake's (CHK) CEO McClendon Gets Wiped Out, Has To Sell Nearly All His Shares
- DSW (DSW) CEO Buys Another 653.6K Shares
- Discover Financial (DFS) CFO Buys 26K Shares
- AAR Corp. (AIR) Chairman/CEO Buys 10K Shares
- Life Time Fitness (LTM) Announces Pledge Of Stock Transactions by CEO
Sepracor, Inc. (Nasdaq: SEPR) CEO, Adrian Adams, bought 50,000 shares on 05/27 at $20.96, brining his stake to 295,000 shares.
Sepracor, Inc. engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada.
Related Categories
Insider TradesStocks Mentioned
-0.37Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
